Xconomy.com -- One big question women often have after getting diagnosed with breast cancer is whether their first round of treatment is really going to work, or whether they need more aggressive therapy to prevent a relapse. Another big one is whether aggressive treatment is likely to work. Now a little diagnostic company from San Diego, called bioTheranostics, has built a test that it says can help doctors and patients better answer these questions.
